CN1150035C - 一种重组质粒及其在疾病防治中的应用 - Google Patents
一种重组质粒及其在疾病防治中的应用 Download PDFInfo
- Publication number
- CN1150035C CN1150035C CNB00132196XA CN00132196A CN1150035C CN 1150035 C CN1150035 C CN 1150035C CN B00132196X A CNB00132196X A CN B00132196XA CN 00132196 A CN00132196 A CN 00132196A CN 1150035 C CN1150035 C CN 1150035C
- Authority
- CN
- China
- Prior art keywords
- plasmid
- growth factor
- recombiant plasmid
- recombination plasmid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 104
- 230000006798 recombination Effects 0.000 title abstract 7
- 238000005215 recombination Methods 0.000 title abstract 7
- 230000006806 disease prevention Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 231100000241 scar Toxicity 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 11
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 11
- 238000012546 transfer Methods 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 22
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 17
- 210000000589 cicatrix Anatomy 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 230000029663 wound healing Effects 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 206010059245 Angiopathy Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000023589 ischemic disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 206010002027 Amyotrophy Diseases 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 210000001627 cerebral artery Anatomy 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 208000001749 optic atrophy Diseases 0.000 claims description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 108010006025 bovine growth hormone Proteins 0.000 claims 1
- WVBBLATZSOLERT-UHFFFAOYSA-N gold tungsten Chemical compound [W].[Au] WVBBLATZSOLERT-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 abstract description 38
- 208000028867 ischemia Diseases 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 5
- 240000007711 Peperomia pellucida Species 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract description 2
- 208000032544 Cicatrix Diseases 0.000 abstract 2
- 230000037387 scars Effects 0.000 abstract 2
- 208000027219 Deficiency disease Diseases 0.000 abstract 1
- 230000007998 vessel formation Effects 0.000 abstract 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 29
- 238000001890 transfection Methods 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 16
- 230000001154 acute effect Effects 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 210000002363 skeletal muscle cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000004043 dyeing Methods 0.000 description 11
- 210000003141 lower extremity Anatomy 0.000 description 11
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 238000013467 fragmentation Methods 0.000 description 8
- 201000002818 limb ischemia Diseases 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 230000003387 muscular Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 210000003606 umbilical vein Anatomy 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 229910000906 Bronze Inorganic materials 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000010974 bronze Substances 0.000 description 3
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 102000057308 human HGF Human genes 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010069729 Collateral circulation Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101150022655 HGF gene Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB00132196XA CN1150035C (zh) | 2000-12-21 | 2000-12-21 | 一种重组质粒及其在疾病防治中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB00132196XA CN1150035C (zh) | 2000-12-21 | 2000-12-21 | 一种重组质粒及其在疾病防治中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1358543A CN1358543A (zh) | 2002-07-17 |
CN1150035C true CN1150035C (zh) | 2004-05-19 |
Family
ID=4595042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB00132196XA Expired - Lifetime CN1150035C (zh) | 2000-12-21 | 2000-12-21 | 一种重组质粒及其在疾病防治中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1150035C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100441226C (zh) * | 2002-04-26 | 2008-12-10 | 中国人民解放军军事医学科学院放射医学研究所 | 用于加速创伤修复及防治并发症的方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1703248A (zh) * | 2002-10-02 | 2005-11-30 | 安琪士摩奇株式会社 | 用于听觉损害的药物制剂 |
WO2006105511A1 (en) * | 2005-03-31 | 2006-10-05 | The General Hospital Corporation | Monitoring and modulating hgf/hgfr activity |
CA2720611C (en) * | 2008-04-09 | 2016-07-12 | Viromed Co., Ltd. | Lyophilized dna formulations for enhanced expression of plasmid dna |
CN101701219B (zh) * | 2009-11-06 | 2013-02-20 | 哈尔滨医科大学 | 编码兔肝细胞生长因子的cDNA及其表达载体和应用 |
MX2016005006A (es) | 2013-10-22 | 2016-07-14 | Viromed Co Ltd | Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito. |
CN106497975A (zh) * | 2016-10-21 | 2017-03-15 | 浙江生创精准医疗科技有限公司 | 基因重组干细胞制剂的制备方法及其在皮肤损伤修复、瘢痕抑制中的应用 |
CN108611367B (zh) * | 2018-04-24 | 2019-11-19 | 北京诺思兰德生物技术股份有限公司 | 一类通过质粒载体介导的基因治疗重组载体 |
US11554179B2 (en) | 2018-07-19 | 2023-01-17 | Helixmith Co., Ltd | Lyophilized pharmaceutical compositions for naked DNA gene therapy |
-
2000
- 2000-12-21 CN CNB00132196XA patent/CN1150035C/zh not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100441226C (zh) * | 2002-04-26 | 2008-12-10 | 中国人民解放军军事医学科学院放射医学研究所 | 用于加速创伤修复及防治并发症的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1358543A (zh) | 2002-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1150035C (zh) | 一种重组质粒及其在疾病防治中的应用 | |
TW201117841A (en) | Pharmaceutical composition for improving myocardial infarction | |
WO2019057219A1 (zh) | Ghrelin活性剂用于诱导干细胞向软骨细胞分化 | |
Meirer et al. | Comparison of the effectiveness of gene therapy with vascular endothelial growth factor or shock wave therapy to reduce ischaemic necrosis in an epigastric skin flap model in rats | |
CN112843229B (zh) | 一种促进皮肤损伤修复的药物在整形外科修复中的应用 | |
CA2378925A1 (en) | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing | |
CN107982536B (zh) | 一种药物作用靶点的组合物和应用 | |
WO2024074119A1 (zh) | 一种重组胶原蛋白及其在软骨修复基质中的用途 | |
CN1339973A (zh) | 糖尿病性局部缺血疾病的基因治疗 | |
CN108324926A (zh) | 干细胞提取物和抗菌肽的组合物及其用途 | |
AU2002247007B2 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
CN1065875C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN114031672A (zh) | 一种多肽及其在制备软骨修复和/或骨关节炎药物中的应用 | |
CN110804100A (zh) | 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物 | |
CN1250287C (zh) | 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用 | |
JP2022549741A (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
CN1251047A (zh) | 刺激神经再生的方法 | |
CN1837239A (zh) | 一种多肽生长因子共聚物及其制备方法与应用 | |
CN100441226C (zh) | 用于加速创伤修复及防治并发症的方法 | |
CN112675294B (zh) | 一种成纤维细胞的制备及在整形外科修复中的应用 | |
RU2664192C1 (ru) | Рекомбинантный ген, кодирующий белок hbd-epo, рекомбинантная плазмидная днк pl610, способ получения рекомбинантного белка hbd-epo, рекомбинантный белок hbd-epo, композиция для специфической индукции регенерации костной ткани, способ специфической индукции регенерации костной ткани | |
CN101818171B (zh) | 人ski基因真核表达载体、制备方法及其应用 | |
CN102858363B (zh) | Hb-egf组合物和其治疗与增强的尿道上皮渗透性相关的病症的应用 | |
CN1167801C (zh) | 重组人vegf腺病毒载体及其应用 | |
CN1284563A (zh) | 携带人肝细胞生长因子基因的重组载体及其在缺血性疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: OPTICS VALLEY HUMANWELL BIOPHARMACEUTICAL CO., LTD Free format text: FORMER OWNER: BEIJING HAITAI LIANHE PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20120904 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: EMISSION AND RADIATION MEDICAL RESEARCH INSTITUTE Free format text: FORMER NAME: RADIATION MEDICINE INST., MILITARY MEDICINE ACADEMY, P.L.A. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 100850 No. 27, Taiping Road, Beijing, two Patentee after: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Patentee after: Beijing Haitai Joint Medical Technology Development Co.,Ltd. Address before: 100850 No. 27, Taiping Road, Beijing, two Patentee before: Institute of Radiation Medicine, Chinese Academy of Military Medical Sciences Patentee before: Beijing Lu Yin Li Hua Pharmaceutical Science Technology Development Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120904 Address after: 100850 No. 27, Taiping Road, Beijing, two Patentee after: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Patentee after: WUHAN OPTICS VALLEY HUMANWELL BIO-PHARMACEUTICAL Co.,Ltd. Address before: 100850 No. 27, Taiping Road, Beijing, two Patentee before: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Patentee before: Beijing Haitai Joint Medical Technology Development Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20040519 |
|
CX01 | Expiry of patent term |